Introduction
Sulfonylureas such as tolbutamide and glyburide are orallyadministrable insulin secretagogues prescribed for the treatment of type 2 diabetes. Both are known to require careful dosing in order to reduce the risk of hypoglycemia in vivo. 1 Exenatide, a synthetic version of exendin-4, is an agonist at the glucagon-like peptide-1 (GLP-1) receptor, 2 and it is a safer means by which to lower levels of blood glucose since it has a reduced ability to induce hypoglycemia. 3 Clinical studies in which sulfonylureas were paired with GLP-1 or exenatide revealed a surprising increase in the incidence of hypoglycemia. 4 The objective of the present study was to investigate a potential molecular mechanism of ATP-sensitive K + channel (K ATP channel) regulation that might explain this adverse drug interaction.
clinical studies demonstrate that combined administration of sulfonylureas with exenatide can induce hypoglycemia in type 2 diabetic subjects. Whereas sulfonylureas inhibit b-cell K ATp channels by binding to the sulfonylurea receptor-1 (sUR1), exenatide binds to the GLp-1 receptor, stimulates b-cell cAMp production and activates both pKA and epac. In this study, we hypothesized that the adverse in vivo interaction of sulfonylureas and exenatide to produce hypoglycemia might be explained by epac-mediated facilitation of K ATp channel sulfonylurea sensitivity. We now report that the inhibitory action of a sulfonylurea (tolbutamide) at K ATp channels was facilitated by 2'-O-Me-cAMp, a selective activator of epac. Thus, under conditions of excised patch recording, the dose-response relationship describing the inhibitory action of tolbutamide at human b-cell or rat INs-1 cell K ATp channels was left-shifted in the presence of 2'-O-Me-cAMp, and this effect was abolished in INs-1 cells expressing a dominant-negative epac2. Using an acetoxymethyl ester prodrug of an epac-selective cAMp analog (8-pcpT-2'-O-Me-cAMp-AM), the synergistic interaction of an epac activator and tolbutamide to depolarize INs-1 cells and to raise [ca 2+ ] i was also measured. This effect of 8-pcpT-2'-O-Me-cAMp-AM correlated with its ability to stimulate phosphatidylinositol 4,5-bisphosphate hydrolysis that might contribute to the changes in K ATp channel sulfonylurea-sensitivity reported here. On the basis of such findings, we propose that the adverse interaction of sulfonylureas and exenatide to induce hypoglycemia involves at least in part, a functional interaction of these two compounds to close K ATp channels, to depolarize b-cells and to promote insulin secretion.
Facilitation of b-cell K ATP channel sulfonylurea sensitivity by a cAMP analog selective for the cAMP-regulated guanine nucleotide exchange factor Epac colin A. Leech, 1 ReseARch pApeR activating protein kinase A (PKA) and the exchange proteins directly activated by cAMP (Epac). 12 Although PKA was previously implicated in the regulation of K ATP channels 13 and also voltage-dependent K + channels 14 in b-cells, new findings demonstrate that Epac proteins, including the isoform known as Epac2, couple cAMP production to K ATP channel inhibition and the potentiation of GSIS from b-cells. For example, a cAMP analog that is a selective activator of Epac potentiates GSIS from mouse islets, 15 and this effect is attributable, at least in part, to its ability to inhibit the activity of b-cell K ATP channels that are also inhibited by GLP-1. [16] [17] [18] The cAMP analogs that produce these effects in b-cells are designated as Epac-selective cAMP analogs (ESCAs). They include 2'-O-Me-cAMP, 8-pCPT-2'-O-Me-cAMP, and the acetoxymethyl ester "prodrug" of 8-pCPT-2'-O-Me-cAMP that is highly effective as an insulin secretagogue. 15 The ability of ESCAs to inhibit K ATP channel activity can be explained by a model in which these compounds activate Epac2 that is in association with nucleotide-binding fold-1 (NBF-1) of the K ATP channel's SUR1 subunit. 6, 17, 19 In the model we have proposed, 20 activated Epac proteins promote Rap GTPase-dependent stimulation of phospholipase C-epsilon (PLCε), 21 with concomitant depletion of plasma membrane-associated phosphatidylinositol 4,5-bisphosphate (PIP 2 ) located at the K ATP channels. Since PIP 2 stimulates K ATP channel activity, 22, 23 ESCAs may act through Epac2, Rap, and PLCε to counteract this effect. Given that PIP 2 also decreases the apparent affinity of K ATP channels for ATP, 22, 23 this model is fully consistent with a recent study demonstrating that Epac activators increase the K ATP channel's apparent affinity for ATP in human b-cells and rat INS-1 cells. 18 Interestingly, one prediction of this model is that Epac2 activation should also increase K ATP channel sulfonylurea sensitivity, and this prediction is tested in the present study. Our findings lead us to conclude that Epac2 activation does in fact increase the sulfonylurea sensitivity of K ATP channels, thereby offering one simple explanation for how a cAMP-elevating agent such as exenatide interacts in vivo with sulfonylureas to depolarize b-cells, to induce excessive insulin secretion, and to promote hypoglycemia. 24 Fig. 1A) . Such findings are consistent with our prior report that a low concentration of 2'-O-Me-cAMP inhibited K ATP channel activity in an ATP-dependent manner. 18 However, when both tolbutamide and 2'-O-Me-cAMP were administered simultaneously, the action of tolbutamide was potentiated (Fig. 1A) . The expanded traces of (Fig. 1B) . This ability of 2'-O-Me-cAMP to facilitate K ATP channel sulfonylurea-sensitivity was most likely mediated by Epac2 because no such action of the ESCA was measured in INS-1 cells expressing a dominant-negative Epac2 in which inactivating G114E and G422D mutations were introduced into the exchange factor's two cAMP-binding domains (Fig. 1C) .
Results
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Thus, the sensitization of K ATP channel sulfonylurea sensitivity reported here cannot be explained by K ATP channel rundown or non-specific channel block by 2'-O-Me-cAMP.
Cumulative dose-response relationships describing the action of tolbutamide (0.1 -100 μM) in the absence or presence of a fixed concentration of 2'-O-Me-cAMP (50 μM) were then constructed by averaging data obtained from multiple excised patches using the experimental design described for 2'-O-Me-cAMP sensitizes K ATP channels to the inhibitory action of gliclazide. It was recently reported that tolbutamide directly activates Epac2. 27 This finding raises the possibility that the binding of tolbutamide to Epac2 rather than SUR1 explains its increased potency to inhibit K ATP channel activity when patches are treated with 2'-O-Me-cAMP. Thus, tolbutamide and 2'-O-Me-cAMP might synergistically activate Epac2 in order to inhibit K ATP channel activity. Although this hypothetical scenario can not be ruled out at the present time, we found that gliclazide, a sulfonylurea that does not directly activate Epac2, 27 inhibited K ATP channel activity in excised patches, and that this action of gliclazide was facilitated by treatment of the patches with 2'-O-Me-cAMP. For such experiments, it was first determined that 2'-O-Me-cAMP (10 μM) potentiated the inhibitory action of tolbutamide (10 μM) at K ATP channels in excised patches of INS-1 cells (Fig. 3A) . It was then demonstrated that gliclazide (50 nM) also inhibited K ATP channel activity in the same patches, and that this inhibitory effect was facilitated by 2'-O-Me-cAMP ( Fig. 3B ; paired t-test). Since gliclazide binds with high affinity to SUR1, yet fails to activate Epac2, 27 it may be concluded that 2'-O-Me-cAMP is capable of facilitating K ATP channel sulfonylurea sensitivity in a manner that is independent of any potential ability of sulfonylureas to activate Epac2 directly. To substantiate this conclusion, a Rap1 activation assay was performed using INS-1 cells expressing recombinant Epac2 and Rap1 (Fig. 3C) . In this assay, neither tolbutamide nor gliclazide activated Rap1 when tested at 3-300 μM or 50-300 nM, respectively. However a significant increase of activated Rap1 was measured in response to combined administration of forskolin (2 μM) and IBMX (100 μM), or after administration of 8-pCPT-2'-O-Me-cAMP-AM (ESCA-AM; 3 μM). These data indicate that in INS-1 Fig. 4A) . For Epac1 and Epac2 the mean threshold crossing values relative to S18 mRNA were 9.13 ± 0.13 (n = 6) and 2.16 ± 0.18 (n = 6), respectively. Using the ΔΔC t method, 29 Epac2 mRNA abundance was calculated to be approximately 125-fold higher than that of Epac1 -1 cells (Fig. 5B) . However, the acetoxymethyl ester of a PKA-selective cAMP analog (6-Bnz-cAMP-AM) 32 was fully active (Fig. 5C) [Ca 2+ ] i since K ATP channel closure leads to depolarization and Ca (Fig. 6A) (Fig. 6B) . Such a supra-additive response is expected if GLP-1 promotes the activation of Epac2, 33 thereby facilitating the inhibitory action of tolbutamide at K ATP channels. Consistent with this concept, tolbutamide and 8-pCPT-2'-O-Me-cAMP-AM also interacted in a supra-additive manner to increase [Ca 2+ ] i (Fig. 6C) . However, no such supra-additive response was measured when tolbutamide was paired with the PKA-selective cAMP analog 6-Bnz-cAMP-AM (Fig. 6D) .
2+ influx in INS-1 cells. As expected, we found that depolarization induced by tolbutamide was potentiated by 8-pCPT-2'-O-Me-cAMP-AM, as measured using INS-1 cells loaded with the voltage-sensitive FRET probes CC2-DMPE and DiSBAC2
Epac activation stimulates PIP 2 hydrolysis in INS-1 cells. We recently proposed that inhibitory effects of Epac activators at K ATP channels are explained by their ability to promote the hydrolysis of plasma membrane PIP 2 . 20 We have now assessed the capacity of Epac activators to promote PIP 2 
hydrolysis by performing live-cell imaging of INS-1 cells virally transduced with a biosensor incorporating the pleckstrin homology domain of PLCδ fused to GFP (PHD-GFP)
. 34 This biosensor is sequestered at the plasma membrane by virtue of its ability to bind PIP 2 , and it is released into the cytosol in response to PIP 2 hydrolysis. 34 When INS-1 cells expressing the PHD-GFP biosensor were stimulated with 8-pCPT-2'-O-Me-cAMP-AM, there occurred a reversible redistribution of the biosensor away from the plasma membrane and into the cytosol (Fig. 7A,B) .
This effect of the ESCA was reproduced upon stimulation of INS-1 cells with GLP-1 (10 nM; data not shown; n = 8 cells).
To obtain independent confirmation that redistribution of the PHD-GFP reporter measured in this manner did in fact correspond to PIP 2 Attention has recently focused on the potential roles of Rap and PLCε as intermediaries linking Epac activation to the inhibition of K ATP channels. 20 This concept was advanced because Epac acts via Rap to stimulate PLCε, thereby hydrolyzing PIP 2 in various cell types. 21 Since PIP 2 is an activator of K ATP channels, and because PIP 2 reduces these channel's sensitivities to both ATP The difference in the threshold crossing values for epac isoforms relative to s18 (Δc t ) was 2.16 ± 0.18 (n = 6) for epac2 and 9.13 ± 0.13 (n = 6) for epac1. These data indicate that epac2 mRNA is expressed at a level significantly higher than that of epac1 (p < 0.001). An additional possibility concerns whether or not PKC activation secondary to PLC stimulation contributes to the inhibitory effect of Epac activators at K ATP channels. This may not be the case since we found that 2'-O-Me-cAMP sensitized K ATP channels to the inhibitory action of sulfonylureas under ATP-free conditions. However, GLP-1 was previously reported to activate PKC in INS-1 cells, 38 and activators of PKC were found to inhibit K ATP channels in an insulin-secreting cell line. 39 
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Given that certain phosphatases are known to be under the control of Ca 2+ /calmodulin, this model is fully consistent with a prior report that calmodulin antagonists prevented the inhibitory action of GLP-1 at mouse b-cell K ATP channels, 43 and that GLP-1 acted independently of PKA to inhibit K ATP channels in rat b-cells.
44
Perhaps more intriguing, it may be that Epac2 itself is a direct target of both 2'-O-Me-cAMP and tolbutamide, a concept recently advanced by Seino and co-workers. 27 In the model of Seino, cAMP and certain sulfonylureas directly bind to and activate Epac2. Since Epac2 interacts with NBF-1 of SUR1, 6, 19, 26 inhibitory actions of sulfonylureas at K ATP channels might be explained by their ability to bind to a conventional sulfonylurea receptor (SUR1) as well as a non-conventional receptor (Epac2). However, findings presented here seem to argue against a model in which Epac2 serves as a physiologically relevant sulfonylurea receptor. For example, we found that tolbutamide failed to activate Rap1 in INS-1 cells expressing Epac2, a finding we interpret to indicate that Epac2 is not directly activated by tolbutamide. Furthermore, in assays of K ATP channel activity, we found that 2'-O-Me-cAMP potentiated the action of gliclazide, a sulfonylurea that failed to activate Epac2. 27 Thus, new findings presented here concerning gliclazide indicate that simultaneous activation of Epac2 by Epac-selective cAMP analogs and sulfonylureas is unlikely to constitute the primary mechanism by which these agents synergistically inhibit K ATP channel function. However, such observations do not exclude the possibility that direct activation of Epac2 by sulfonylureas can occur under experimental conditions or in cell lines not used in our studies.
In conclusion, new findings presented here offer a novel "K ATP dependent" mechanistic explanation for the adverse interaction of high dose exenatide and sulfonylureas to depolarize b-cells, to stimulate excessive insulin secretion, and to induce hypoglycemia in type 2 diabetic subjects.
Materials and Methods
Cell culture. Human islets provided by the NIH ICR centers were cultured 18 and b-cells were identified on the basis of rat insulin 2 gene promoter-directed expression of enhanced yellow fluorescent protein (EYFP). 45 INS-1 cells were passaged in culture as described previously.
46 Dominant-negative Epac2 26 was stably expressed in INS-1 cells using methods described previously for Epac1. Measurements of membrane potential. Perforated patch recording of the membrane potential was performed using the SES bath and pipette solutions described above, but with the pipette solution supplemented with nystatin. 16 For FRET-based determination of membrane potential, cells grown in 96-well plates were loaded with 3 μM CC2-DMPE and 3 μM DiSBAC 2 (Invitrogen) for 40 min at room temperature. Cells were excited using 400 nm excitation light and the emission light was measured at 460 nm and 580 nm using a FlexStation 3. An increase in the 460/580 emission ratio signifies membrane depolarization.
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Rap1 activation assay. Activation of Rap1 was assayed by Western blot using cell lysates from INS-1 cells transiently transfected with FLAG-epitope tagged Rap1 and Epac2. Transfection was performed using Lipofectamine Plus Reagent (Invitrogen). The methods used in this Ral-GDS-RBD-GST pull-down assay employing glutathione-conjugated agarose beads are described elsewhere. 30 The activated GTP-bound form and the total amount of Rap1 were detected using an anti-FLAG M2 monoclonal antibody conjugated to HRP (Sigma-Aldrich; Cat. No. A8592).
Quantitative PCR for Epac. RNA was isolated from INS-1 cells using RNEasy kits (Qiagen). RNA concentration and purity was assessed using a NanoDrop ND-1000 spectrofluorimeter. QPCR reactions were performed using QuantiTect Sybr-green one-step kits (Qiagen) with approximately 100 ng of template RNA. Reactions were performed using an MJ MiniOpticon cycler with 35 cycles of: 94 o C for 15 s, 60 o C for 30 s and 72 o C for 30 s followed by a melting curve analysis from 60 o C to 94 o C. Reaction products were run on 2% agarose gels and bands were cut out and gel extracted using QIAquick kits (Qiagen). Product identity was confirmed by direct sequencing at an in-house core facility. The PCR primers were: Epac1 (sense) CATGGCAAGGGGCTGGTGAC, (antisense) GTCCTGCTTGTCCACACGCAG. Epac2 (sense) CGCCATGCAACCATCGTTACC, (antisense) GAGCCCGTTTCCATAACACC. Ribosomal S18 was used as the reference template with the following primers: (sense) GCCATCACTGCCATTAAGGG, (antisense) CCAGTCTGGGATCTTGTACTG. Primers were tested at different starting template concentrations to validate their equal efficiencies. Threshold crossing (C t ) values were set manually and the difference between the C t value for S18 and Epac (ΔC t ) was calculated for each reaction. Relative expression levels for Epac1 and Epac2 were determined using the ΔΔC t method. 29 ΔC t values were entered into Origin 8 software for statistical analysis using ANOVA.
PKA activation assay. PKA activity in lysates of INS-1 cells was measured using a PepTag cAMP-Dependent Protein Kinase Assay (Promega). Prior to lysis, INS-1 cells were exposed to cAMP analogs for 30 min while equilibrated at 37°C in RPMI 1640 medium.
PIP 2 biosensor traslocation assay. INS-1 cells were split onto coverslips and placed in RPMI 1640 medium supplemented with 2% FBS and 10 mM HEPES. A viral vector expressing the pleckstrin homology domain of PLCδ fused to enhanced green fluorescent protein (PHD-GFP) 34 was introduced at a multiplicity of infection of 50 and the cells were transduced overnight before 
